Scholar Rock Holding Corp. Aktie News

Scholar Rock Holding Corporation (SRRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

New York City-based Commodore Capital sold nearly 1.5 million shares of Scholar Rock, a net position change of about $51 million. The transaction value was approximately 2.5% of Commodore Capital LP's 13F reportable assets under management.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will...

Scholar Rock Holding Corporation ( SRRK ) Q3 2025 Earnings Call November 14, 2025 8:00 AM EST Company Participants Laura Ekas David Hallal - CEO & Chairman of the Board Akshay Vaishnaw - President of R&D, Member of Scientific Advisory Board and Director R. Keith Woods Vikas Sinha - Chief Financial Officer Conference Call Participants Mani Foroohar - Leerink Partners LLC, Research Division Eric ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today reported financial results for...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 30,000 shares of its common stock to 1 newly hired employee, consisting of inducement stock options to purchase an aggregate of 17,143 shares of common stock and inducement restricted stock units, covering an aggregate of 12,857...

Earnings season often shines a spotlight on well-known mega-caps, but it can also bring opportunities for lesser-known companies to shine. Below are three stocks—each down significantly in 2025—that could stage a comeback if their upcoming earnings updates hit the right notes.

Scholar Rock Holding Corporation (SRRK) is a clinical-stage biotech focused on targeted therapies for neuromuscular and fibrotic diseases, with Apitegromab as its lead asset. SRRK's Apitegromab achieved strong phase 3 results in spinal muscular atrophy, showing meaningful motor function gains and robust safety as an add-on therapy. The recent stock correction was due to manufacturing site issue...